BiotechTube

Hetrombopag Olamine Tablet；Ciclosporin Soft Capsule

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Sever Aplastic Anaemia

Conditions

Sever Aplastic Anaemia

Trial Timeline

Sep 3, 2020 → Oct 22, 2020

NCT ID
NCT05088174

About Hetrombopag Olamine Tablet；Ciclosporin Soft Capsule

Hetrombopag Olamine Tablet；Ciclosporin Soft Capsule is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for Sever Aplastic Anaemia. The current trial status is completed. This product is registered under clinical trial identifier NCT05088174. Target conditions include Sever Aplastic Anaemia.

What happened to similar drugs?

20 of 20 similar drugs in Sever Aplastic Anaemia were approved

Approved (20) Terminated (6) Active (0)
✅Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
✅tacrolimusAstellas PharmaApproved
✅AlefaceptAstellas PharmaApproved
✅CefiderocolShionogiApproved
✅Donepezil HClEisaiApproved
✅Donepezil Hydrochloride (Aricept)EisaiApproved
✅KHK4827-Active + KHK4827-PlaceboKyowa KirinApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05088174Phase 1Completed

Competing Products

20 competing products in Sever Aplastic Anaemia

See all competitors
ProductCompanyStageHype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
44
Drotrecogin alfa (activated)Eli LillyPhase 2
35
CT-P13 SC Auto-Injector + Placebo Auto-InjectorCelltrionPhase 3
44
CT-P17 + EU-approved HumiraCelltrionPhase 3
40
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
47
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
44
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
47
CS-3150Daiichi SankyoPhase 3
40
tacrolimusAstellas PharmaApproved
43
enzalutamideAstellas PharmaPhase 1
29
Isavuconazonium Injection [Cresemba] + PlaceboAstellas PharmaPhase 3
32
AlefaceptAstellas PharmaApproved
43
Placebo + SCD-044_Low Dose (Dose 1) + SCD-044_Intermediate Dose (Dose 2) + SCD-044_High Dose (Dose 3)Sun PharmaceuticalPhase 2
35
Tildrakizumab 100 mg + PlaceboSun PharmaceuticalPhase 3
44
Tildrakizumab + Placebo + Tildrakizumab + Tildrakizumab + Tildrakizumab + Etanercept + PlaceboSun PharmaceuticalPhase 2/3
42
CefiderocolShionogiApproved
50
eritoran tetrasodium + PlaceboEisaiPhase 3
40
Donepezil HClEisaiApproved
43
Donepezil Hydrochloride (Aricept)EisaiApproved
35
KHK4827 + PlaceboKyowa KirinPhase 3
40